ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, Chief Financial Officer, will participate in a fireside chat at the upcoming Guggenheim Nantucket Therapeutics Conference. The presentation is scheduled for September 28, 2022 at 11:15am ET.

A webcast of the presentation will be accessible through the “Investors and Media” section of the Company’s website, Following the live webcast, a replay will be available at the same location.


ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.

Learn more about who we are, what we do, and how we do it at

INVESTOR RELATIONS ImmunoGen Anabel Chan 781-895-0600

MEDIA ImmunoGen Courtney O’Konek 781-895-0600


FTI Consulting Robert Stanislaro 212-850-5657

Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more ImmunoGen Charts.
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more ImmunoGen Charts.